ROLE OF SERIN/ THREONINE KINASE INHIBITOR IN THERAPY NON-ALCOHOLIC STEATOHEPATITIS AND ALCOHOLIC HEPATITIS by Lestari, Novriantika
JKK, Volume 6, No 3, Oktober 2019: 101-109 101
p-issn 2406-7431; e-issn 2414-041
Role of Serin/ Threonine Kinase Inhibitor in Therapy Non-Alcoholic
Steatohepatitis and Alcoholic Hepatitis
Novriantika Lestari
Department of Pharmacology, Faculty of Medicine and Health Sciences, University of Bengkulu
Email: novriantika.lestari@gmail.com
ABSTRACT
Liver fibrosis is a reversible response to a wound healing with marked accumulation of extracellular matrix which
caused by injury to the liver. Liver fibrosis can be caused by various factors including alcohol and non-alcohol
steatohepatitis. The process of fibrosis serves to localize the inflammation during chronic exposure. The hepatic
stem cell (HSC) has a key role in the pathogenesis of liver fibrosis. The HSC activation is characterized by increased
profibrogenic mediators including members of the TGF-β superfamily. In order to enable signal transduction, the
mediator needs to bind to its receptors. The serine/ threonine kinase receptor is a receptor that binds to the TGF-β
superfamily ligand, including TGF-β, BMP, activin and other mediators. The ligand receptor-binding activity will
stimulate signal transduction that will translocate into the nucleus and phosphorylate various transcription factors
that play a role in cell proliferation, differentiation, or apoptosis. There is currently no standard therapy for liver
fibrosis. Based on the central role of the serine/ threonine kinase receptor in the pathogenesis of liver fibrosis, it is
thought that the use of serine/ threonine kinase inhibitorsis a promising therapy.
1. Introduction
Liver fibrosis is an excessive accumulation of
extracellular matrix including collagen tissue
in various chronic liver diseases. The process
of fibrosis is closely related to a wound
healing, and it serves to localize the
inflammation during chronic exposure.1 In
acute liver injury, the fibrosis process is
transient, but in chronic injury, the
accumulation of extracellular matrix
willincreasing and the liver parenchyma will
form a scar tissue progressively.2
Without an adequate treatment, liver
fibrosis may progress to liver cirrhosis and
hepatocellular carcinoma. Cirrhosis is the end
stage of liver fibrosis, characterized by the
formation of nodules in the liver. This
aberration is accompanied by impaired
hepatic blood flow, leading to an increase in
porta venous pressure.3 Portal hypertension is
a major cause of mortality and morbidity in
liver cirrhosis, characterized by the formation
of ascites and esophageal varices. Nodular
hyperplasia formed in cirrhosis, may develop
into multiple adenomas, and multiple
carcinomas, called hepatocellular carcinoma.
The progression of fibrosis to cirrhosis can
occur within 15-20 years.1
2. Liver Fibrosis
The liver parenchyma is composed of
epithelial cells (hepatocytes), endothelial cells
and non-parenchymal cells, the stellate
hepatic cells (HSC) and Kupffer cells. Liver
vascularization is derived from a sinusoid
which has a microvascular structure.
Sinusoids have endothelial walls that
separated from hepatocytes with
subendothelial spaces which are the site of
HSC.2
HSC has a key role in the pathogenesis
of liver fibrosis. HSC was previously known
as the Ito cell,liposit or perisinusoidal cellthat
known to be liver cells that produce collagen.
These cells are present in the
Disseperisinusoid space, which is
thesubendothelial spaces between the
hepatocytes and endothelial cells. In a normal
liver, HSC is a quiescence cell and serves as a
retinoid deposit and maintains a basale
membrane matrix.2,4
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HSC activation shows the conversion of
a retinoid-rich cell that is resting into a
proliferating, fibrogenic and contractile cell.
Although the other cell populations may
contribute to the accumulation of extracellular
matrix, HSC activation is the most dominant
mechanism in the liver fibrosis.5 HSC
activation involves two main processes that
are initiation and perpetuation. If the injury
subsides, there will be a resolution process.6
The initiation process is an early stage
of hepatic injury, that characterized by an
inflammatory response and oxidative stress,
leading to changes in gene expression and
phenotype. The perpetuation process is the
stage to maintain an active phenotype. The
activated hepatic stellate cells form the
miofibroblasts, characterized by loss of
retinoid retention, increased secretion of
fibrogenesis mediators, increased α-smooth
muscle actin (α-SMA) expression, and
increased proliferation and contractility.
Miofibroblasts willdo theproliferation in
response to various cytokines and growth
factors. Proliferation of miofibroblastswill be
followed by an accumulation of extracellular
matrix. Miofibroblasts may be inactivated or
being apoptosis progressively if etiology is
eliminated.6,7,8
The stimulation of HSC activation
comes from paracrine stimulation by injured
hepatocyte cells, kupffer cell, endothelial cells
and platelets. The stimulus includes various
mediators, including TGF-β, BMP, PDGF,
VEGF, MMP and TIMP. The stimulus causes
a quiescence HSC to become active.9,10
In active HSC, the synthesis of
endogenous TGF-β also increased
significantly. TGF-β is the main mediator that
stimulates the quiet HSC to be active. HSC
activation is the most dominant route in the
course of liver fibrosis. The TGF-β
mechanism will promoting the liver fibrosis
by inhibiting the degradation of extracellular
matrix by suppressing the Metalloprotein
Matrix (MMP) and promoting its natural
inhibitor Tissue Inhibitor of Metalloproteinase
(TIMP). Furthermore, TGF-β will inducing
the formation of miofibroblasts by the
mechanism of Epithelial Mesenchymal
Transformation (EMT) in epithelial cells. The
third mechanism is to induce matrix
production through Smad andnon-Smad
pathways.11
The main causes of hepatic fibrosis
include hepatitis B virus infection, hepatitis C,
alcohol, Non Alcoholic Steatohepatitis
(NASH), haematocromatosis, Wilson's
disease, antitrypsin α-1 deficiency,
autoimmune (primary biliary cirrhosis), and
liver intoxication (drugs or nutrients ). The
course of liver fibrosis disease is often
asymptomatic, the morbidity and mortality
will be occur after the stage of cirrhosis of the
liver is reached. And, until now there is no
standard treatment for liver fibrosis.
3. NASH (Non-Alcoholic Steato Hepatitis)
Non-alcoholic fatty liver disease (NAFLD)
refers to the spectrum of diseases, that ranging
from fatty liver to liver inflammation and
fibrosis, called non-alcoholic steatohepatitis
(NASH). Obesity and type II diabetes are
strongly associated with the development of
NAFLD. 10-15% of steatosis patients will
develop into NASH, and 20-25% of NASH
patients eventually develop into liver cirrhosis
that significantly increases the risk for
hepatocellular carcinoma.12
The pathogenesis of NASH consists of
two stages: the occurrence of normal liver
steatosis, especially as a result of insulin
resistance in the periphery, that causing
adipose cells and muscle cells oxidize lipids,
leading to the release of free fatty acids. Fatty
acids are then absorbed by the liver. Then,
thefat accumulation will be form as a
triglycerides in the liver. The second process
is steatohepatitis, in which the accumulation
of fat causes inflammation that mediated by
103 Novriantika Lestari, Role Of Serin/ Threonine Kinase Inhibitor In Therapy
oxidative stress and fibrosis process, mediated
bythe secretion of various cytokines.12,13
4. Alcoholic Hepatitis
Accumulation of ethanol in the liver can cause
three different pathological pathologies,
namely fatty liver (alcoholic steatosis),
alcoholic hepatitis and cirrhosis. Alcoholic
steatosis is the most common form of liver
injury and reversible when alcohol
consumption is stopped. More serious
alcoholic liver disease includes alcoholic
hepatitis characterized by persistent liver
inflammation, and cirrhosis characterized by
progressive liver fibrosis.14,15
The process of liver fibrosis begins in
the perivenular region and is affected by the
amount of alcohol consumed. Perivenular
fibrosis and fibronectin deposition occur in
40% -60% of patients who consume alcohol
more than 40-80 g / day for approximately 25
years. Perivenular sclerosis is considered a
risk factor for the development of liver injury
from alcohol to fibrosis or cirrhosis. Alcohol-
induced liver cirrhosis is a micronodular,
butoccasionally it can be mixed both
amicronodular and macronodularry.14
Alcohol-induced liver damage leads to
the production of cytokines that mediate
proinflammatory and profibrogenic responses,
including TGF-β, TNF-alpha, and PDGF.
TGF-β plays an important role in underlying
alcohol-induced fibrosis because ethanol
metabolism will increase TGF-β production,
while hepatocyte cell, Kupffer cell and HSC
apoptosis also produce TGF-β, active TGF-β
has been proven to induce fibrosis in
transgenic mouse models , and TGF-beta will
synergizes with alcohol in inducing oxidative
stress thus increasing alcohol-induced liver
damage.16,17
The various mediators and signal
transduction pathways involved in liver
fibrosis have been described. In order to
enable signal transduction, the mediator needs
to bind to their receptors. Among these
receptors, an enzyme family called serine/
threonine kinase has been known to be
involved in the activation and proliferation of
hepatic stellate cells. The serine/ threonine
kinase receptor is a receptor that binds to the
TGF-β superfamily ligand, including TGF-β,
BMP, and other mediators. Ligand-receptor
binding activity has a wide function in various
cell physiology processes including
proliferation, differentiation and apoptosis.
Abnormal activity will disrupt cellular
homeostasis and cause fibrosis malignancy.
Returning the ligand-receptor binding activity
as in normal circumstances can be a potential
therapeutic target.
5. Serine/ Threonine Kinase Receptor
Human as multi-cellular organisms lives in
complex environments with multiple signal
transduction pathways that contribute to their
life survival. Serine/ threonine kinase is one of
the important enzymes in the signal
transduction process that play a role in cell
proliferation, differentiation, and apoptosis.
Serine/ threonine is an enzyme that catalyzes
the phosphorylation of serine and threonine
residues from target proteins using ATP.18
The serine/ threonine kinase receptor is
a single transmembrane proteinthat consisting
of extracellular domains for binding to ligands
and intracellular catalytic domains facing
cytosol. The activation process of serine/
threonine kinase receptor is triggered by
dimerization of two monomers of serine/
threonine kinase receptors in line with
autophosphorylated in intracellular domains
so that catalytic activity increases. As a
consequence, it will be produce biochemical
signals and activate intracellular signal
transduction.19,20
There are two classes of serine/
threonine kinase receptors which are
structurally similar homodimers. The thype II
receptors act as a primary receptor that bind to
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ligand, whereas the type I receptors act as
transducers that will activate signals on the
downstream. The type I will be activated after
the ligand binds to type II and phosphorylates
serine and threonine.20
The serine/ threonine kinase
receptortransduces signals from TGF-β
superfamily. TGF-β superfamily includes a
large number of structural and functional
proteins such as Transforming Growth Factor-
β (TGF-β), Bone morphogenetic protein
(BMP), activinsinhibin, Growth
Differentiation Factors (GDF), and Anti
Muellerian Hormone (AMH). The serine/
threonine kinase receptorthat has been known
to play a role in liver fibrosis include TGF-β
Receptor (TβR), BMP Receptor (BMPR),
Activin Receptor (ActR).11,19
The association between the serine/
threonine kinase receptor and its ligand in the
form of TGF-β superfamily will primarily
phosphorylate the Smad protein to mediate
signal transduction to intracelluler. The
members of the Smad protein family can be
classified into 3 groups based on their
function. The first group consists of Smad1,
Smad2, Smad3, Smad5, and Smad8 which are
receptor-regulated Smad (R-Smad). The
second group is Smad4 which is a common
Smad (Co-Smad). The third group is Smad6
and Smad 7 which is the inhibitory of Smad
(I-Smad). R-Smad will bind to the serine/
threonine kinase receptor which is attached to
the membrane and activated through its kinase
activity. Co-Smad will bind to the activated
R-Smad to form a complex that translocates to
the nucleus. I-Smad works in opposition to R-
Smad as a signal transduction inhibitor of
TGF-β superfamily.21In addition to
activateSmad, the bond between the serine/
threonine kinase receptor with the TGF-β
superfamily ligand also activates the non-
Smad pathway.
HSC activation is an important marker
in the pathogenesis of liver fibrosis. The
process of transdifferentation of inactive
HSCs to miofibroblasts that trigger
extracellular matrix accumulation and scar
formation is a main process in the course of
the disease. Serine/ threonine kinase has a
mitogenic potential that plays a role in its
activation and proliferation.
1. TGF-β Receptors (TβR)
TGF-β Receptor is a serine/ threonine
kinase receptor that binds to a TGF-β ligand, a
cytokine of TGF-β superfamily that consists
of more than 35 structurally related proteins.
The protein bonds form a homodimers and
after its activation, it will regulates many
cellular responses such as proliferation and
apoptosis, differentiation and migration. TGF-
β The receptor consists of TGF-β type 1
receptor (Activin receptor-like kinase 5-
ALK5) and type II.11
The TGF-β signal starts from the
binding of TGF-beta to its serine/ threonine
kinase receptor ie TGF-β type I and type II
receptors. TGF-β bound to TGF-β type II
receptors will cause type II receptors
phosphorylating serine residues and threonine
to activate type I TGF-β receptor. Type I
TGF-β receptor will then activate the Smad
and non Smad pathways.11,22
TGF-β consists of TGF-β1, TGF-β2,
and TGF-β3 which will be observed in
various fibrosis diseases. The release of TGF-
β by hepatocytes undergoing necrosis due to
liver injury is one of the earliest signals in
HSC activation that results in HSC
transdifferentiation being miofibroblasts.
Signal transduction TGF-βwill inhibits HSC
apoptosis and induces HSC to synthesize
extracellular matrix such as collagen and
fibronectin massively. TGF-β will suppress
the production of matrix degrading proteases
(MMP) and increase the protease inhibitors
such as Tissue Inhibitor of Metalloproteinase
(TIMP).8
TGF-β will be activating the TGF-β
type 1 receptor and cause a phosphorylation
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of Smad2 and Smad3. pSmad2 and pSmad3
will bind to Smad4 to translocate to the
nucleus and control the transcription of gene
expression. At liver, TGF-β signals will
participate in the fibrogenic response through
hepatic stellate cell activation so that the
TGF-β signaling in HSC plays a role in
fibrosis progression. In addition to activating
Smad2 / 3, the TGF-β bond on the receptor
also stimulates the non-Smad pathway, which
activates mitogen-activating protein kinases
(ERK, p38 and JNK), phosphatidylinositol 3
kinase (PI3K) / Akt and small
GTPase.11Transduction signals via the TGF-β
pathway are the main mechanisms underlying
liver fibrosis.
2. BMP Receptors
The signal transduction of Bone
Morphogenetic Protein (BMP) is as complex
as TGF-β. BMP Receptors consist of type I
and II receptors. BMP receptor type I consists
of BMPRIA (ALK3) to bind BMP and
BMPRIB ligands (ALK6) to bind BMP and
Growth Differentiation Factors (GDF)
ligands. BMP was first identified as a protein
that induces endochondral bone formation and
cartilage. There are 15 BMPs as members of
the BMPs subfamily. BMP2, BMP4, BMP 7,
and BMP 9 are known to be involved in
fibrosis of the liver.23,24,25
BMP signal starts from BMP binding
with its serine/ threonine kinase receptor ie
BMP type I and type II receptor. BMPs that
bind to BMPR II will cause type II receptors
to phosphorylate serine and threonine residues
at BMP type I receptor. The type I BMP
receptor then becomes active and
subsequently phosphorylates Smad 1, Smad 5,
and smad 8. The activated Smad complex will
translocate into nucleus and bind to the Smad-
responsive element to begin the transcription
process.23
BMP will promotes liver fibrosis
through the same mechanism as TGF-β by
inhibiting the degradation of extracellular
matrix, inducing the formation of
miofibroblasts, and inducing matrix
production via Smad and non-Smad pathways.
However, there are differences in their effect
on HSC proliferation activity. BMP does not
affect the proliferation of HSC, in contrast to
TGF-β which affects HSC proliferation. It can
be concluded that BMP signals work in
activated HSCs in the transdifferentiation
process and retain the form of
miofibroblasts.23,26
Signal transduction from Growth
Differentiation Factors (GDF) also uses BMP
receptors. There is an overexpression of GDF
15 in cases of chronic liver injury. This is
because GDF 15 also induces the formation of
an extracellular matrix by suppressing Matrix
Metalloprotein (MMP) and promoting its
natural inhibitor Tissue Inhibitor of
Metalloproteinase (TIMP).27
3. Activin Receptor (ActR)
Activin is a member of the TGF-β
superfamily known to have activity to
stimulate the production of Follicle
Stimulating Hormone (FSH) in the pituitary
gland. Activin is further known to have
activity against proliferation and other cell
differentiation. The activin receptor resembles
a TGF-β receptor that after active
phosphorylation of Smad2 and Smad3.28
In chronic liver injury, activin binding
of the receptor plays a role in inhibiting the
proliferation of hepatocytes and causing
apoptosis. Activin also plays a role in the
formation of extracellular matrix and
increases the proliferation of miofibroblasts.28
Given the central role of binding of the
serine/ threonine kinase receptorwith its
ligand in intracellular signal transduction,
deregulation of serine/ threonine kinase
activity may promote fibrosis, apoptosis, and
malignancy. It also suggests that the return of
serine/ threonine kinase activity as in normal
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tissue is a treatment approach that can be
developed.
6. Serine/ Threonine Kinase Inhibitor
In a liver fibrosis, there is an increased
expression of serine/ threonine kinase
receptorin activated HSC as a result of
stimulus from TGF β superfamily. In the last
of few decades, the development of inhibitor
serine/ threonine kinase receptors has been
widely practiced. Initially the development of
this drug is intended as an anti-tumor, but the
use of such inhibitors for the treatment of non-
malignant diseases, especially fibrosis showed
satisfactory results. Based on the central role
of TGF-β superfamily in pathogenesis of liver
fibrosis, it is thought that the use of serine/
threonine kinase inhibitorsis a promising
therapy.
Serine/ threonine kinase inhibitors
prevent and block vital pathways with
targeted signal molecules that play an
important role in the survival of a cell. The
serine/ threonine kinase inhibitor can
translocate through the plasma membrane and
interact with the cytosolic domain of the
serine / threonine kinase receptor. The serine /
threonine kinase inhibitorwill inhibits the
catalytic activity of the kinase domain by
disrupting the binding of ATP or substrate
binding.
1. TGF-β Receptor Inhibitor
The signal transduction pathway TGF-β1 /
Smad is the main mechanism underlying liver
fibrosis disease, therefore it can be a clear
therapeutic target to prevent or treat liver
fibrosis. Several experimental studies have
identified a number of alternative approaches
to block the action of TGF-β, including the
use of dissolved TGFR2 (sTβRII.Fc), anti-
sense TGF-β1 oligonucleotides, and TGFR1
kinase activity inhibitors. Of these alternatives,
clinical studies have begun with the use of
TGFR1 kinase inhibitors in patients with
fibrosis.29
Galunisertib(LY2157299 monohydrate)
is a small molecule that inhibits TGF-β
receptor I receptors that specifically decrease
levels of phosphorylation of SMAD2, thus
inhibiting the Smad pathway. This inhibitory
effect was performed on research using mouse
and human animals, so it used to be
teraupetiktarger in fibrosis and cancer cells.
Currently,Galunisertib isintensively studied as
an antifibrotic and has completed phase II
clinical trials. In clinical trials, the use of
galunisertib can be used as a drug in
hepatocellular carcinoma that does not
respond to sorafenib.30,31
The mechanism of action of galunisertib
that inhibits the receptor TGF-β receptor I is
by inhibiting the phosphorylation of SMAD2.
In an ex vivo study of TGF-β-induced liver-
slice preparations, galunisertib was shown to
decrease the expression of TGF-β and α-SMA
mRNAs. α-SMA is known to be a marker of
liver fibrosis. Galunisertib also proven to
decrease the formation of extracellular matrix
and collagen type I.
The antifibrotic effects of galunisertib
have been shown by many experiments. In all
animal models attempted for liver fibrosis, the
use of galunisertib showed antifibrotic effects,
among other models of experimental animals
with CCl4 induction, coledocus duct ligation
(BDL), dimethylnitrosamine(DMN),
diethylnitrosamine (DEN), and thioacetamide
(TAA).32
Other drugs are EW-7197 which
provides anti-fibrotic effects with inhibition of
the TGF-β Smad pathway and ROS signal
transduction. EW-7197 also inhibits HSC
activation and expression of α-SMA and
collagen type I. These effects have been
demonstrated both in vitro and in vivo
including in animal models with CCl4
induction, choledocus duct ligation (BDL),
and bleomycin induction. These data support
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that EW-7197 efficiently reduces in vivo and
in vitro fibrosis and may be a therapeutic
option for the treatment of liver fibrosis.
Currently EW-7197 is in phase II clinical
trials.33
2. BMP Receptor Inhibitor
The development of TGF-β inhibitors
has been done for a long time and some drugs
have entered the clinical trial stage. However,
the development of molecules that inhibit
BMP activity has only been done in recent
years. Dorsomorphin is known to inhibit
binding activity to BMP receptor type I as
well as blocking BMP activity in
phosphorylation of 1/5/8 Smad.
Dorsomorphin is also known to inhibit activin
activity and affect the signal TGF-β. Currently
Dorsomorphin is in phase I clinical trials for
the treatment of solid tumors.24
Development of BMP receptor
inhibitors is currently performed on 2-
aminopyridine (K02288). K02288 is known to
have more specific activity inhibiting BMP
binding with its receptor so the receptorcan
not phosphorylate Smad 1, Smad 5, or Smad 8
proteins that play a role in inducing matrix in
fibrosis process. This inhibitory activity does
not affect signal transduction from other TGF-
β superfamily.24
3. Activin Receptor Inhibitor
Inhibitory activity against receptor
activin is still continuing. Selective inhibition
has been obtained from Folastatin
administration, gene therapy isolated from
ovarian follicles. For the development of new
drug use there is a non-selective effect,
wherein Dorsomorphin which has inhibitory
activity against activin receptors also inhibits
BMP receptor. SB-43 in addition to inhibiting
receptors activin also inhibits signal TGF-β.34
Liver fibrosis has a complex mechanism.
The involvement of serine/ threonine kinase
has been known to its mechanism and its
binding with the ligand mediates signal
transduction that plays an important role in
fibrosis to malignancy. The use of serine /
threonine kinase inhibitorsis a potential
therapy considering there is no standard
therapy for liver fibrosis. These inhibitors still
require further study so that humans can using
it as liver fibrosis therapy.
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